+Search query
-Structure paper
Title | Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. |
---|---|
Journal, issue, pages | MAbs, Vol. 14, Issue 1, Page 2072455, Year 2022 |
Publish date | May 12, 2022 |
Authors | Tatsuhiko Ozawa / Hideki Tani / Yuki Anraku / Shunsuke Kita / Emiko Igarashi / Yumiko Saga / Noriko Inasaki / Hitoshi Kawasuji / Hiroshi Yamada / So-Ichiro Sasaki / Mayu Somekawa / Jiei Sasaki / Yoshihiro Hayakawa / Yoshihiro Yamamoto / Yoshitomo Morinaga / Nobuyuki Kurosawa / Masaharu Isobe / Hideo Fukuhara / Katsumi Maenaka / Takao Hashiguchi / Hiroyuki Kishi / Isao Kitajima / Shigeru Saito / Hideki Niimi / |
PubMed Abstract | Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 ...Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an assay and prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants. |
External links | MAbs / PubMed:35543180 / PubMed Central |
Methods | EM (single particle) / X-ray diffraction |
Resolution | 3.1 - 3.75 Å |
Structure data | EMDB-33045: SARS-CoV-2 spike glycoprotein in complex with neutralizing antibody UT28K PDB-7x7o: |
Source |
|
Keywords | VIRAL PROTEIN / SARS-CoV-2 / spike / antibody |